# A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

> **NCT03343054** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 28 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** talazoparib

## Key facts

- **NCT ID:** NCT03343054
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2021-01-11
- **Final completion:** 2024-07-18
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343054, "A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03343054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*